Therapeutic targeting of the p53 pathway in cancer stem cells

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 12, 2012, Pages 1161-1174

  Prabhu, Varun V ^a   Allen, Joshua E ^a,b   Hong, Bo ^a   Zhang, Shengliang ^a   Cheng, Hairong ^a   El Deiry, Wafik S ^a,c  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Cancer stem cells; Cancer therapy; P53; P53 pathway; P53 pathway restoration; P53 restoration; Stem cells

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CONTUSUGENE LADENOVEC; GENDICINE; HLI 98; ISOINDOLE DERIVATIVE; LONTUCIREV; MI 219; MIRA 1; NSC 143491; NSC 176327; NSC 254681; NSC 279287; NSC 66811; NUCLEAR EXPORT INHIBITOR; PHIKAN 083; PRIMA 1; PROTEIN P53; PXN 727; PXN 822; RITA; SCH 529074; SERDEMETAN; SJ 172550; TDP 521252; TDP 665759; TENOVIN DERIVATIVE; TERPHENYL DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XI 006;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CYTOLOGY; DOWNSTREAM PROCESSING; DRUG MECHANISM; DRUG TARGETING; EMBRYONIC STEM CELL; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84869387218     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.726985     Document Type: Review

References (131)

1. Zhao T, Xu Y. p53 and stem cells: new developments and new concerns. Trends Cell Biol 2010;20:170-5
2. Chen F, Wang W, El-Deiry WS. Current strategies to target p53 in cancer. Biochem Pharmacol 2010;80:724-30
3. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008;20:90-6
4. Mandinova A, Lee SW. The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med 2011;3:64rv1
5. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009;458:1127-30
6. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007;7:165-8
7. Essmann F, Schulze-Osthoff K. Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol 2012;165:328-44
8. Sax JK, Fei P, Murphy ME, et al. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 2002;4:842-9
9. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25
10. Wu GS, Burns TF, McDonald ER III, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-3
11. Sax JK, El-Deiry WS. p53 downstream targets and chemosensitivity. Cell Death Differ 2003;10:413-17
12. Stegh AH. Targeting the p53 signaling pathway in cancer therapy-the promises, challenges and perils. Expert Opin Ther Targets 2012;16:67-83
13. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci 2001;114:4139-40
14. Nevins Jr. The Rb/E2F pathway and cancer. Hum Mol Genet 2001;10:699-703
15. Tang Y, Zhao W, Chen Y, et al. Acetylation is indispensable for p53 activation. Cell 2008;133:612-26
16. Zhao Y, Lu S, Wu L, et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 2006;26:2782-90
17. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009;137:609-22
18. Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010;17:901-11
19. Johnson RA, Shepard EM, Scotto KW. Differential regulation of MDR1 transcription by the p53 family members. Role of the DNA binding domain. J Biol Chem 2005;280:13213-19
20. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53
21. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445:661-5
22. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006;127:1323-34
23. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60
24. Kastan MB. Wild-type p53: tumors can't stand it. Cell 2007;128:837-40
25. Lu C, El-Deiry WS. Targeting p53 for enhanced radio-and chemo-sensitivity. Apoptosis 2009;14:597-606
26. Lee J, Moon C. Current status of experimental therapeutics for head and neck cancer. Exp Biol Med (Maywood) 2011;236:375-89
27. O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004;6:611-23
28. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005;8:61-74
29. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006;98:298-300
30. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011;4:16
31. Lu C, Wang W, El-Deiry WS. Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol Ther 2008;7:2039-46
32. Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 2006;103:11003-8
33. Kravchenko JE, Ilyinskaya GV, Komarov PG, et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 2008;105:6302-7
34. Rosenbluth JM, Mays DJ, Pino MF, et al. A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 2008;28:5951-64
35. Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-Specific p53 Mutant Reactivation. Cancer Cell 2012;21:614-25
36. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011;17:313-19
37. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-59
38. Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008;88:459-63
39. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
40. O'Brien CA, Kreso A, Dick JE. Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol 2009;19:71-7
41. Driessens G, Beck B, Caauwe A, et al. Defining the mode of tumour growth by clonal analysis. Nature 2012;488(7412):527-30
42. Schepers AG, Snippert HJ, Stange DE, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012;337:730-5
43. Chen J, Li Y, Yu TS, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488(7412):522-6
44. Xu Y. A new role for p53 in maintaining genetic stability in embryonic stem cells. Cell Cycle 2005;4:363-4
45. Lin T, Chao C, Saito S, et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005;7:165-71
46. Spike BT, Wahl GM. p53, Stem Cells, and Reprogramming: tumor Suppression beyond Guarding the Genome. Genes Cancer 2011;2:404-19
47. Lee KH, Li M, Michalowski AM, et al. A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells. Proc Natl Acad Sci USA 2010;107:69-74
48. Maimets T, Neganova I, Armstrong L, Lako M. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells. Oncogene 2008;27:5277-87
49. Krizhanovsky V, Lowe SW. Stem cells: the promises and perils of p53. Nature 2009;460:1085-6
50. Puzio-Kuter AM, Levine AJ. Stem cell biology meets p53. Nat Biotechnol 2009;27:914-15
51. Utikal J, Polo JM, Stadtfeld M, et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009;460:1145-8
52. Marion RM, Strati K, Li H, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009;460:1149-53
53. Li H, Collado M, Villasante A, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009;460:1136-9
54. Kawamura T, Suzuki J, Wang YV, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009;460:1140-4
55. Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009;460:1132-5
56. Tapia N, Scholer HR. p53 connects tumorigenesis and reprogramming to pluripotency. J Exp Med 2010;207:2045-8
57. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005;7:1074-82
58. Sarig R, Rivlin N, Brosh R, et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med 2010;207:2127-40
59. Flores I, Blasco MA. A p53-dependent response limits epidermal stem cell functionality and organismal size in mice with short telomeres. PLoS ONE 2009;4:e4934
60. Zhou Z, Flesken-Nikitin A, Nikitin AY. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res 2007;67:5683-90
61. Meletis K, Wirta V, Hede SM, et al. p53 suppresses the self-renewal of adult neural stem cells. Development 2006;133:363-9
62. Mendrysa SM, Ghassemifar S, Malek R. p53 in the CNS: perspectives on Development, Stem Cells, and Cancer. Genes Cancer 2011;2:431-42
63. Armesilla-Diaz A, Bragado P, Del Valle I, et al. p53 regulates the self-renewal and differentiation of neural precursors. Neuroscience 2009;158:1378-89
64. Hede SM, Nazarenko I, Nister M, Lindstrom MS. Novel perspectives on p53 function in neural stem cells and brain tumors. J Oncol 2011;2011:852970
65. Akala OO, Park IK, Qian D, et al. Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/-multipotent progenitors. Nature 2008;453:228-32
66. Bondar T, Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 2010;6:309-22
67. Korkaya H, Wicha MS. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 2007;21:299-310
68. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-98
69. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50
70. Jiang J, Hui CC. Hedgehog signaling in development and cancer. Dev Cell 2008;15:801-12
71. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003;22:6598-608
72. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007;28:339-63
73. de Sousa EM, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res 2011;17:647-53
74. Pannuti A, Foreman K, Rizzo P, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010;16:3141-52
75. Merchant AA, Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-40
76. Tao L, Roberts AL, Dunphy KA, et al. Repression of mammary stem/progenitor cells by p53 is mediated by Notch and separable from apoptotic activity. Stem Cells 2011;29:119-27
77. Liu Y, Elf SE, Miyata Y, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009;4:37-48
78. Cheng T, Rodrigues N, Shen H, et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000;287:1804-8
79. van Os R, de Haan G, Dykstra BJ. Hematopoietic stem cell quiescence: yet another role for p53. Cell Stem Cell 2009;4:7-8
80. Liu Y, Elf SE, Asai T, et al. The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle 2009;8:3120-4
81. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004;101:14228-33
82. Bunting KD, Zhou S, Lu T, Sorrentino BP. Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. Blood 2000;96:902-9
83. Allen JE, Hart LS, Dicker DT, et al. Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther 2009;8:2194-205
84. Vilgelm A, Wei JX, Piazuelo MB, et al. DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Oncogene 2008;27:2170-6
85. Joseph B, Hermanson O. Molecular control of brain size: regulators of neural stem cell life, death and beyond. Exp Cell Res 2010;316:1415-21
86. Nekulova M, Holcakova J, Coates P, Vojtesek B. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett 2011;16:296-327
87. Godar S, Ince TA, Bell GW, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008;134:62-73
88. Du Z, Li J, Wang L, et al. Overexpression of DeltaNp63alpha induces a stem cell phenotype in MCF7 breast carcinoma cell line through the Notch pathway. Cancer Sci 2010;101:2417-24
89. Van Maerken T, Speleman F, Vermeulen J, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 2006;66:9646-55
90. Zhao Z, Zuber J, Diaz-Flores E, et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010;24:1389-402
91. Mizuno H, Spike BT, Wahl GM, Levine AJ. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci USA 2010;107:22745-50
92. Paolella BR, Havrda MC, Mantani A, et al. p53 directly represses Id2 to inhibit the proliferation of neural progenitor cells. Stem Cells 2011;29:1090-101
93. Zheng H, Ying H, Yan H, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008;455:1129-33
94. Grinstein E, Wernet P. Cellular signaling in normal and cancerous stem cells. Cell Signal 2007;19:2428-33
95. Pelicci PG. Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence? J Clin Invest 2004;113:4-7
96. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003;423:255-60
97. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003;100:15178-83
98. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66:6063-71
99. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009;4:e6816
100. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-15
101. Nalls D, Tang SN, Rodova M, et al. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 2011;6:e24099
102. Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008;8:266
103. Amson R, Pece S, Lespagnol A, et al. Reciprocal repression between P53 and TCTP. Nat Med 2011;18(1):91-9
104. Koziol MJ, Garrett N, Gurdon JB. Tpt1 activates transcription of oct4 and nanog in transplanted somatic nuclei. Curr Biol 2007;17:801-7
105. Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010;140:62-73
106. Ligon KL, Huillard E, Mehta S, et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007;53:503-17
107. Kippin TE, Martens DJ, van der Kooy D. p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. Genes Dev 2005;19:756-67
108. Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Curr Cancer Drug Targets 2006;6:15-37
109. Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 2009;9:626-38
110. Freed-Pastor WA, Mizuno H, Zhao X, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012;148:244-58
111. Ginestier C, Monville F, Wicinski J, et al. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 2012;30:1327-37
112. Ginestier C, Charafe-Jauffret E, Birnbaum D. p53 and cancer stem cells: The mevalonate connexion. Cell Cycle 2012;11(14):2583-4
113. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8
114. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012. doi:10.1016/j.semcancer.2012.04.001
115. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15
116. Morel AP, Lievre M, Thomas C, et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3:e2888
117. Chen C, Wei Y, Hummel M, et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One 2011;6:e16466
118. Asiedu MK, Ingle JN, Behrens MD, et al. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 2011;71:4707-19
119. Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010;5:e12445
120. Chang CJ, Chao CH, Xia W, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011;13:317-23
121. Kogan-Sakin I, Tabach Y, Buganim Y, et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 2011;18:271-81
122. Dong P, Karaayvaz M, Jia N, et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2012. doi:10.1038/onc.2012.334
123. Zhang Y, Yan W, Jung YS, Chen X. Mammary epithelial cell polarity is regulated differentially by p73 isoforms via epithelial-to-mesenchymal transition. J Biol Chem 2012;287:17746-53
124. Li L, Wang L, Wang Z, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012;21:266-81
125. Ito T, Zimdahl B, Reya T. aSIRTing control over cancer stem cells. Cancer Cell 2012;21:140-2
126. Cicalese A, Bonizzi G, Pasi CE, et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009;138:1083-95
127. Huang C, Zhang XM, Tavaluc RT, et al. The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol Ther 2009;8:2186-93
128. Janicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 2008;15:959-76
129. Vousden KH. Outcomes of p53 activation-spoilt for choice. J Cell Sci 2006;119:5015-20
130. Donehower LA. Does p53 affect organismal aging? J Cell Physiol 2002;192:23-33
131. Gatza CE, Dumble M, Kittrell F, et al. Altered mammary gland development in the p53+/m mouse, a model of accelerated aging. Dev Biol 2008;313:130-41